Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA To Review Qualified Health Claim For Xangold - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

FDA To Review Qualified Health Claim For Xangold

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Cognis Nutrition & Health, LaGrange, IL, has petitioned FDA for a qualified health claim (QHC) linking consumption of Xangold® natural lutein esters to a reduced risk of two major eye diseases: age-related macular degeneration and cataracts. FDA has slated the QHC (2004Q-0180) for review and is expected to respond to Cognis’ petition within eight months. The proposed petition states: “Consumption of 12 mg Xangold lutein esters per day may reduce the risk of age-related macular degeneration (AMD) and cataract formation. FDA has determined that the evidence is supportive, but not conclusive, for this claim. (This food/dietary supplement provides _ mg lutein esters per serving).”

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters